Jove
Visualize
Contact Us

Related Experiment Videos

Mitoxantrone.

T I Poirier

    Drug Intelligence & Clinical Pharmacy
    |February 1, 1986
    PubMed
    Summary

    Mitoxantrone, an anthraquinone antineoplastic agent, shows significant efficacy in treating metastatic breast cancer, acute leukemias, and non-Hodgkin

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Evaluation of drug interaction microcomputer software: an updated comparison.

    Hospital pharmacy·1995
    Same author

    Clinical and ethical perspectives on rationing of high-cost drugs.

    The Annals of pharmacotherapy·1995
    Same author

    Linking a policy on nonformulary drugs to the FDA's therapeutic-potential classification system.

    American journal of hospital pharmacy·1994
    Same author

    Pharmacists' and physicians' attitudes toward pharmaceutical marketing practices.

    American journal of hospital pharmacy·1994
    Same author

    Survey of clinical pharmacokinetic software for microcomputers.

    Hospital pharmacy·1992
    Same author

    Evaluation of patient counseling microcomputer software programs.

    Hospital pharmacy·1992
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Medical Oncology
    • Pharmacology

    Background:

    • Mitoxantrone is an anthraquinone antineoplastic agent.
    • It shares structural and mechanistic similarities with anthracyclines.
    • Its primary elimination is via hepatic metabolism, with a terminal half-life of approximately 40 hours.

    Purpose of the Study:

    • To review the efficacy and dosing of mitoxantrone in various cancers.
    • To explore its potential in cases of anthracycline resistance.

    Main Methods:

    • Literature review of mitoxantrone's activity and pharmacokinetic profile.
    • Analysis of reported clinical activity in different cancer types.
    • Examination of dosing strategies for solid tumors, lymphomas, and leukemias.

    Main Results:

    • Mitoxantrone demonstrates significant activity in metastatic breast cancer, acute leukemias, and non-Hodgkin's lymphoma.
    • Activity is also noted in head and neck cancer, Hodgkin's disease, myeloma, bladder, prostate, non-small-cell lung, and liver cancers.
    • Incomplete cross-resistance with anthracyclines is suggested, with reported activity in anthracycline-refractory breast cancer, leukemias, and lymphomas.

    Conclusions:

    • Mitoxantrone is an effective chemotherapeutic agent with broad applicability.
    • It offers a treatment option for patients refractory to anthracyclines.
    • Specific dosing guidelines exist for different hematologic and solid malignancies.

    Related Experiment Videos